Universal CAR-T Cells therapy(Shenzhen Geno-Immune Medical Institute)

N/A

Report date: 2023/11/01 20:08:59

Base Information

Drug NameUniversal CAR-T Cells therapy(Shenzhen Geno-Immune Medical Institute)
Drug Alias NameCLL-1, CD33, CD38 and/or CD123-specific universal CAR- T cellsuniversal CAR T-cell products
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionInterleukin-3 receptor subunit alpha modulatorsLymphocyte differentiation antigen CD38 modulatorsMyeloid cell surface antigen CD33 modulators +[4] 
TargetsInterleukin-3 receptor subunit alphaLymphocyte differentiation antigen CD38Myeloid cell surface antigen CD33 +[4] 
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShenzhen Geno-Immune Medical Institute
China Registration ClassN/A

Develop Information

Active CompaniesShenzhen Geno-Immune Medical Institute
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A